Cyclo(Arg-Gly-Asp-D-Phe-Cys) |
カタログ番号GA21303
One-Click Copy Product Info
|
Cyclo(Arg-Gly-Asp-D-Phe-Cys)は通常cRGDfCと略称され、環状RGDペプチドであり、インテグリンαvβ3に高い親和性と選択性を示す。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 862772-11-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cyclo(Arg-Gly-Asp-D-Phe-Cys)は通常cRGDfCと略称され、環状RGDペプチドであり、インテグリンαvβ3に高い親和性と選択性を示す[1]。マウス胚性幹細胞(mESCs)をCyclo(Arg-Gly-Asp-D-Phe-Cys)ペプチドで処理することは、一部の細胞に早期外胚葉系譜マーカーを発見させる[2]。Cyclo(Arg-Gly-Asp-D-Phe-Cys)は主に、リポソームとその他の送達システムの修飾に使われ、よって腫瘍組織への標的薬物送達を実現する[3-4]。
マウス胚性幹細胞で、Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5mM；24時間)は転写因子Oct 4、Sox 2とNanogを下方制御した[2]。
References:
[1]. Nallamothu R, Wood GC, Pattillo CB, et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. Aaps Pharmscitech. 2006 Jun; 7: E7-16.
[2]. Hazenbiller O, Duncan NA, Krawetz RJ. Reduction of pluripotent gene expression in murine embryonic stem cells exposed to mechanical loading or Cyclo RGD peptide. BMC Cell Biology. 2017 Dec; 18: 1-5.
[3]. Chen Z, Deng J, Zhao Y, et al. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. International journal of nanomedicine. 2012 Jul 18: 3803-3811.
[4]. Xia Y, Chen Y, Hua L, et al. Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy. International Journal of Nanomedicine. 2018 Oct 30: 6929-6939.
| 細胞実験[1]: | |
細胞株 | マウス胚性幹細胞(mESCs) |
準備方法 | マウス胚性幹細胞(mESCs)をタイプ1のコラーゲンマトリックスに埋め込んだ。手短に言えば、8から10段階のmESCsを、トリプシン化し、β-グリセロールリン酸培地(βGP)で再懸濁した。βGP培地は、高糖5 × DMEM粉末培地で構成され、10mM βGPと標準細胞培養手続きに等しいFBS、NEAA、ペニシリン-ストレプトマイシン溶液とβMEを添加した。1つのコラーゲン構造物を調製するために、1,000,000の細胞を200μLのβGP培地に再懸濁し、800μLのウシコラーゲンタイプI溶液(3mg/mL)と20μLの水酸化ナトリウムで混合した。インテグリンの研究について、Cyclo(Arg-Gly-Asp-D-Phe-Cys) (cRGDfC)ペプチドを3%のクエン酸に溶解し、これをmESC-Col I溶液に添加し、よって最終濃度が0.5mMのcRGDfCに達成する。最終的に、cRGDfCの存在と存在しない状況で、mESC-Col I溶液を12ウェルのプレートにピペットし、37℃、5% CO2の加湿インキュベーターで重合させた。 |
反応条件 | 0.5mM; 24時間 |
アプリケーション | Cyclo(Arg-Gly-Asp-D-Phe-Cys)は、mESCsで、転写因子Oct 4、Sox 2とNanogを下方制御した。 |
References: | |
| Cas No. | 862772-11-0 | SDF | |
| Formula | C24H34N8O7S | M.Wt | 578.65 |
| 溶解度 | DMSO: 50 mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7282 mL | 8.6408 mL | 17.2816 mL |
| 5 mM | 345.6 μL | 1.7282 mL | 3.4563 mL |
| 10 mM | 172.8 μL | 864.1 μL | 1.7282 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)